Utilities of amide compounds
    1.
    发明授权
    Utilities of amide compounds 有权
    酰胺化合物的实用性

    公开(公告)号:US08106051B2

    公开(公告)日:2012-01-31

    申请号:US12081662

    申请日:2008-04-18

    摘要: Compounds having an activity to enhance the expression of apoAI are provided, which are used as medicaments.Compounds of formula (I): in which ring A and Ar1 are independently a monocyclic or bicyclic aromatic carbocyclic group or aromatic heterocyclic group, each of which may be optionally substituted, or the like; R is a hydrogen or the like; Z is oxygen or the like; Y1 and Y2 are a hydrogen, a lower alkyl, or the like; n is an integer of 0 to 2; the broken line is the presence or absence of a bond; and the wavy line represents a cis- or trans-geometrical isomerism with respect to the double bond; are disclosed.

    摘要翻译: 提供具有增强载脂蛋白A表达活性的化合物,其用作药物。 式(I)的化合物:其中环A和Ar 1独立地是单环或双环芳族碳环基或芳族杂环基,其各自可以被任选取代;等等; R为氢等; Z是氧等; Y1和Y2是氢,低级烷基等; n为0〜2的整数, 虚线是存在或不存在债券; 并且波浪线表示相对于双键的顺式或反式几何异构体; 被披露。

    Isoxazole derivatives as peroxisome proliferator-activated receptors agonists
    2.
    发明申请
    Isoxazole derivatives as peroxisome proliferator-activated receptors agonists 审中-公开
    异恶唑衍生物作为过氧化物酶体增殖物激活受体激动剂

    公开(公告)号:US20070054902A1

    公开(公告)日:2007-03-08

    申请号:US10581322

    申请日:2004-11-29

    摘要: A compound of formula (I): (wherein R1-R10 are each independently hydrogen, halogen, optionally substituted lower alkyl or the like, X1 is —O—, —S—, —NR11— (wherein R11 is hydrogen, lower alkyl or the like), —CR12R13CO—, —(CR12R13)mO—, —O(CR12R13)m- (wherein R12 and R13 are each independently hydrogen or lower alkyl and m is a integer between 1 and 3) or the like, X2 is a bond, —O—, —S—, —NR14— (wherein R14 is hydrogen, lower alkyl or the like, R14 and R6 can be taken together with the neighboring atom to form a ring) or —CR15R16— (wherein R15 and R16 are each independently hydrogen or lower alkyl, R15 and R6 or R10 can be taken together with the neighboring carbon atom to form a ring, R16 and R9 can be joined together to form a bond), X3 is COOR17, C(═NR17)NR18OR19 or the like), a pharmaceutically acceptable salt or a solvate thereof.

    摘要翻译: 式(I)的化合物:其中R 1〜R 10各自独立地为氢,卤素,任选取代的低级烷基等,X 1, / SUP>是-O - , - S - , - NR 11 - (其中R 11是氢,低级烷基等),-CR 12 - (CR 12)13 - , - (CR 12), - (CR 12) (其中R 12和R 12各自独立地为氢或低级烷基,m为1和...之间的整数) 3)等,X 2是一个键,-O - , - S-,-NR 14 - (其中R 14是 氢,低级烷基等,R 14和R 6可以与相邻原子一起形成环)或-CR 15 R 16 - (其中R 15和R 16各自独立地是氢或低级烷基,R 15和 R 6或R 10可以与相邻的碳原子一起形成环,R 16和R 9, S 可以连接在一起形成键),X 3是COOR 17,C(-NR 17)NR 18 其药学上可接受的盐或其溶剂化物。

    New utilities of amide compounds
    7.
    发明申请
    New utilities of amide compounds 有权
    酰胺化合物的新用途

    公开(公告)号:US20080221112A1

    公开(公告)日:2008-09-11

    申请号:US12081662

    申请日:2008-04-18

    摘要: Compounds having an activity to enhance the expression of apoAI are provided, which are used as medicaments.Compounds of formula (I): in which ring A and Ar1 are independently a monocyclic or bicyclic aromatic carbocyclic group or aromatic heterocyclic group, each of which may be optionally substituted, or the like; R is a hydrogen or the like; Z is oxygen or the like; Y1 and Y2 are a hydrogen, a lower alkyl, or the like; n is an integer of 0 to 2; the broken line is the presence or absence of a bond; and the wavy line represents a cis- or trans-geometrical isomerism with respect to the double bond; are disclosed.

    摘要翻译: 提供具有增强载脂蛋白A表达活性的化合物,其用作药物。 式(I)的化合物:其中环A和Ar 1独立地是单环或双环芳族碳环基或芳族杂环基,其各自可以被任选取代;等等; R为氢等; Z是氧等; Y 1和Y 2是氢,低级烷基等; n为0〜2的整数, 虚线是存在或不存在债券; 并且波浪线表示相对于双键的顺式或反式几何异构体; 被披露。

    Chromene-3-carboxylate derivatives
    8.
    发明授权
    Chromene-3-carboxylate derivatives 失效
    色烯-3-羧酸酯衍生物

    公开(公告)号:US06218427B1

    公开(公告)日:2001-04-17

    申请号:US09242898

    申请日:1999-04-26

    IPC分类号: A61K3135

    摘要: The present invention provides a compound of the formula (I): wherein R1, R2, R3 and R4 are each independently hydrogen, optionally substituted alkyl, hydroxy, optionally substituted alkoxy or the like, R5 is optionally substituted alkyl, optionally substituted aryl, optionally substituted heterocyclic or the like, R6 is hydrogen, optionally substituted alkyl or the like, R7 is hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heterocyclic or the like, A is S or O and a broken line represents presence or absence of a bond, pharmaceutically acceptable salt or hydrate thereof and a pharmaceutical composition or a pharmaceutical composition for use as an endothelin receptor antagonist, a peripheral circulation insufficiency-improving agent or a macrophage foam cell formation inhibitor comprising the compound.

    摘要翻译: 本发明提供式(I)的化合物:其中R 1,R 2,R 3和R 4各自独立地为氢,任选取代的烷基,羟基,任选取代的烷氧基等,R 5为任选取代的烷基,任选取代的芳基, 取代的杂环等,R 6是氢,任选取代的烷基等,R 7是氢,任选取代的烷基,任选取代的烷氧基,任选取代的芳基,任选取代的杂环等,A是S或O,虚线代表 存在或不存在键,其药学上可接受的盐或水合物,以及用作内皮素受体拮抗剂的药物组合物或药物组合物,外周循环功能不足改善剂或包含该化合物的巨噬细胞泡沫细胞形成抑制剂。

    Indole Derivative Having Pgd2 Receptor Antagonist Activity
    10.
    发明申请
    Indole Derivative Having Pgd2 Receptor Antagonist Activity 有权
    具有Pgd2受体拮抗剂活性的吲哚衍生物

    公开(公告)号:US20090030014A1

    公开(公告)日:2009-01-29

    申请号:US11989138

    申请日:2006-07-20

    摘要: The present invention creates an indole derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further a therapeutic agent for treating allergic diseases.A compound of the generic formula (I) wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a 3- to 8-membered nitrogen-containing non-aromatic heterocyclic ring etc.; R1, R2, R3, R4 and R5 are independently a hydrogen atom or a halogen atom etc.; R6 is C2-C4 alkyloxy etc.; R7 is independently a halogen atom etc.; R8 is independently C1-C4 alkyl etc.; R9 is carboxy etc.; Y is a single bond etc.; M is sulfonyl etc.; L1, L2 and L3 are a single bond or alkylene optionally containing one or two heteroatoms etc.; n is 0 etc.; q is 0 etc.; a pharmaceutically acceptable salt or hydrate thereof.

    摘要翻译: 本发明产生具有DP受体拮抗活性的吲哚衍生物和包含所述化合物作为活性成分的药物组合物,还有用于治疗过敏性疾病的治疗剂。 通式(I)的化合物,其中环A是芳族碳环等; 环B为3〜8元含氮非芳族杂环等; R1,R2,R3,R4和R5独立地是氢原子或卤素原子等; R6是C2-C4烷氧基等; R7独立地为卤素原子等; R8独立地为C1-C4烷基等。 R9是羧基等。 Y是单键等; M是磺酰基等。 L1,L2和L3是任选含有一个或两个杂原子等的单键或亚烷基; n为0等 q为0等; 其药学上可接受的盐或水合物。